Navigation Links
First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

and muscle stiffness.

COPAXONE(R) is now approved in 48 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In Europe, COPAXONE(R) is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. In North America, COPAXONE(R) is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA). COPAXONE(R) is a registered trademark of Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

See additional important information at http://www.copaxone.com/pi/index.html or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing gen
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:8/27/2015)... , August 27, 2015 Itamar ... a private investment in public equity (PIPE) deal, in ... million in Itamar Medical.   Through this ... of Itamar Medical and will work closely with the ... According to the investment agreement, Itamar Medical will ...
(Date:8/27/2015)... Aug. 27, 2015  Zimmer Biomet Holdings, Inc. (NYSE ... announced that it will be participating in the Goldman ... Goldman Sachs offices in London ... Company Founded in 1927 and headquartered in ... leader in musculoskeletal healthcare.  We design, manufacture and market ...
(Date:8/27/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... of new cancer therapies, today announced that it will ... ending June 30, 2015 on Friday, September 4, 2015. ... business update conference call and live webcast for investors, ...
Breaking Medicine Technology:Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3
... Oct. 14 ZyStor Therapeutics, Inc., a biotechnology company ... the treatment of Lysosomal Storage Diseases using the Company,s ... it has received clearance from the U. S. Food ... for its first drug candidate, ZC-701, an enzyme replacement ...
... Company (NYSE: LLY ) today announced the sale ... AG, one of the world,s largest chemical companies. The ... operation with a focus on producing high-quality active pharmaceutical ... In connection with the sale of the site, the ...
Cached Medicine Technology:ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 2ZyStor Therapeutics, Inc. Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 3Lilly to Sell Tippecanoe Manufacturing Site to Evonik Industries 2Lilly to Sell Tippecanoe Manufacturing Site to Evonik Industries 3Lilly to Sell Tippecanoe Manufacturing Site to Evonik Industries 4
(Date:8/27/2015)... ... August 27, 2015 , ... In ... legal marijuana industry with the launch of its Doobster platform, a HIPAA-compliant mobile ... order products from their smart phones and tablets. Well, Doobster, “The App ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... scheduled for October 27-29, 2015 in San Jose, CA. The first event ... focus on the void that exists where battery development and energy storage innovation ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor of ... third doctoral program at its main campus in Reading: Doctor of Nursing Practice. , ... to prepare advanced practice nurses for the highest level of clinical nursing practice. ...
(Date:8/27/2015)... ... August 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue ... of 2016. The new facility will be located at US Highway 19 North and Highlands ... on August 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... ... , ... NetDimensions is once again named among TrainingIndustry.com’s annual Top ... only to effectively deliver, curate and administer great programs, but also measure the impact ... six consecutive years, NetDimensions has maintained its position on this Top 20 list. This ...
Breaking Medicine News(10 mins):Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3
... States added farm-raised fish and shrimp to a growing list ... Thursday. ,The US Food and Drug Administration ... until importers could prove the shipments were free of unsafe ... urged a recall of up to 450,000 Chinese tires because ...
... south Florida has found that Rheumatologists substantially overestimate ... which may lead to inaccurate evaluations ... for lifestyle modifications. ,The rheumatologists consistently ... in performing activities of daily living, such as ...
... labeled as a mentally ill person, which can ... result in a higher rate of unemployment, lower earnings ... Each year, one in four U.S. adults suffers from ... of Mental Health. ,In a recently published ...
... Gehrig's disease mystery, UCLA, Italian chemists may have solved ... key role in a particular form of amyotrophic ... a progressive, fatal neuro-degenerative disorder that strikes without warning. ... and biochemistry, has studied the protein copper-zinc superoxide dismutase ...
... order can rest assured that their male offspring will take after ... to the daughters, especially in the case of red deer. ... that may prove useful for their sons, may not have the ... ,The boffins also state that though this study was carried out ...
... flower essences, is an effective stress reliever which neither ... to any side effects or addiction, says a scientific ... five flower essences-Rock Rose to alleviate terror and panic, ... inattentiveness, Star of Bethlehem to ease shock, and Cherry ...
Cached Medicine News:Health News:US to Detain Seafood Imports from China 2Health News:Rheumatologists Underestimate the Patients Ability to Work 2Health News:Boffins a Step Closer to Solving Puzzle of Lou Gehrig's Disease 2Health News:Boffins a Step Closer to Solving Puzzle of Lou Gehrig's Disease 3Health News:Successful Dads Have Not So Successful Daughters 2
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
The Livewire steerable electrophysiology catheter is uniquely designed with an ergonomic handle and patented steering mechanism to provide smooth, precise catheter tip movement, even during lengthy e...
... feature 20 bipolar-spaced electrodes along a ... of mapping resolution in atrial fibrillation ... 20-pole catheter enables more accurate pinpointing ... 10-pole catheter systems. The result: greater ...
Livewire TC steerable ablation catheters are designed for the RF ablation of arrhythmias. They are available in a variety of curves and configurations, including bi-directional catheters for added fl...
Medicine Products: